Tasly Pharmaceutical Hits Day High with 5.52% Surge in Stock Price

Tasly Pharmaceutical Group Co., Ltd. has experienced a notable increase of 5.52% on March 27, 2026, reaching an intraday high of CNY 14.65. This performance stands in contrast to the China Shanghai Composite, which recorded a modest gain of 0.63% for the day. Over the past week, Tasly has shown a positive trend with a 2.76% increase, while the broader index has declined by 1.09%. Despite this day's strong performance, Tasly's long-term growth metrics indicate challenges. The company has faced a decline in net sales at an annual rate of -9.48% and a decrease in operating profit of -2.22% over the last five years. Additionally, recent financial results reveal a significant drop in net profit, falling by 55.59% to CNY 112.86 million. With a market capitalization of CNY 22,001 million, Tasly operates within the pharmaceuticals and biotechnology sector. The stock's price-to-earnings ratio stands at 24.00, and it offers a dividend yield of 2.79%. However, the company has underperformed the China Shanghai Composite over various time frames, including the past year and three years.